drugset
drugset / Trial / NCT05456425

A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium

NCT05456425 ↗

Phase 3 Active not recruiting 660 enrolled Cloudbreak Therapeutics, LLC
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective is to evaluate the safety and efficacy of low dose and high dose CBT-001 eye drop dosed twice daily for 24 months compared to vehicle in reducing conjunctival hyperemia and preventing pterygium progression in eyes with pterygia.

Timeline

Start
2022-06-30
Primary completion
2026-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject CBT-001 Unknown 0.1 % Topical
Subject CBT-001 Unknown 0.2 % Topical

Indications

pterygium